CN1666977A - L-chelated magnesium arginine - Google Patents
L-chelated magnesium arginine Download PDFInfo
- Publication number
- CN1666977A CN1666977A CN 200410016924 CN200410016924A CN1666977A CN 1666977 A CN1666977 A CN 1666977A CN 200410016924 CN200410016924 CN 200410016924 CN 200410016924 A CN200410016924 A CN 200410016924A CN 1666977 A CN1666977 A CN 1666977A
- Authority
- CN
- China
- Prior art keywords
- magnesium
- arginine
- people
- lack
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004475 Arginine Substances 0.000 title abstract description 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title abstract description 17
- 229940047608 chelated magnesium Drugs 0.000 title description 2
- 239000011777 magnesium Substances 0.000 claims abstract description 63
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 52
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 49
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229930064664 L-arginine Natural products 0.000 claims abstract description 7
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 7
- 239000013522 chelant Substances 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 229910017976 MgO 4 Inorganic materials 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 235000009697 arginine Nutrition 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 7
- 230000035790 physiological processes and functions Effects 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- 238000010170 biological method Methods 0.000 abstract 1
- 230000003862 health status Effects 0.000 abstract 1
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 239000011575 calcium Substances 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 208000008167 Magnesium Deficiency Diseases 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 235000004764 magnesium deficiency Nutrition 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 2
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YLBYBUBUHYIQDF-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;magnesium Chemical compound [Mg].OC(=O)[C@@H](N)CCCN=C(N)N YLBYBUBUHYIQDF-WCCKRBBISA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010020559 Hyperacusis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- -1 shows as it Chemical compound 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention provides a new molecule belongs to soft magnesium quality in soft matter. L-arginine chelating magnesium made through chemical biological method, it can supply the needed magnesium and arginine to living body. It can be used to protect several kinds of diseases bring by magnesium lack and arginine lack and can make people in inferior-health status to recover to health status. Comparing to the magnesium supply product now, it is easy to dissolve and absorb, pure and safety of its quality and no poison effect. It is a new substance that more accord with people's physiological function need and matching with people's bioenergy conversion. The figure is its formula.
Description
Technical field
The invention belongs to recruit's structure of biological medicine field of health care products, be particularly related to a kind of recruit and be the L-L-Argininum Mg of Chelate, this invention comes true the design design that the L-arginine combines with magnesium elements, and novel substance can change the actual state that metallic element magnesium is difficult for being absorbed by the body; The recruit L-L-Argininum Mg of Chelate that forms can replenish the necessary arginine of organism and treat and prevent various relevant diseases with the molecule of magnesium, also can adjust the sub-health state of human body.
Background technology
Magnesium be at present known to one of several macroelements of needed by human, be the 4th in its macroelement content in vivo, have tangible biological significance.It is the moiety of bone and tooth that the physiological function of magnesium mainly shows as it, is the essential element of substance metabolisms such as sugar, protein, is the important activator of high-energy phosphate bond transferring enzyme in the body, is the antagonist of calcium ion excitation.In case lacks magnesium, will cause many disadvantageous effects in the body, produce a series of illnesss such as tired, nauseating, muscle spasm, heart rate quickening, psychiatric disorder, disorientation health.
The magnesium that contains 20-30g in the adult human body approximately, account for 0.05% of human body body weight, it is that form with phosphoric acid salt and carbonate is present in bone and the tooth that 60% magnesium is wherein arranged approximately, and magnesium can discharge the normal magnesium level in blood and the body tissue of keeping in the bony segment in needs.
The physiological function of magnesium:
1, activate the activity of plurality of enzymes:
Kind of enzymatic reaction surplus magnesium participates in 300 as the activator of plurality of enzymes.Magnesium can form mixture and activating enzyme system with many important component in the cell such as Triphosaden, or direct activator activating enzyme system as enzyme.The plurality of enzymes system will give play to the important physical function with magnesium in the body.Magnesium is the structural promotor of some enzymes, keeps the stable space conformation of these enzymes.Mg
2+Also play the effect of lewis' acid, promptly it can influence the character with its bonded " substrate ", more helps substrate and combines with the active centre of enzyme.This is Mg
2+Of paramount importance form to the enzymic activity influence.
2, potassium, calcium channel there is restraining effect.
3, to bone and nervimuscular effect:
To the effect of bone, 60% magnesium is stored in bone and the tooth in the human body, and magnesium changes and strengthened the structure of bone, makes bone have higher intensity.In adamantine forming process, magnesium has play a part important.If lack magnesium in the body, no matter then calcium pickup all can only form the extremely low enamel of hardness, and this dental tissue is easy to be subjected to the corrosion of acid.
To nervimuscular effect: magnesium makes neuromuscular excited identical with restraining effect with calcium, no matter magnesium or calcium are low excessively in the blood, neural muscle excitability all increases, otherwise then sedative effect is arranged.But magnesium and calcium have antagonistic action again, and competition combines with some enzyme, shows opposite effect aspect neuromuscular function.The nervus centralis that is caused by magnesium and the block at muscle contact place can be by the calcium antagonisms.
Because magnesium plays an important role in the contraction of skeletal muscle and unstriated muscle, so magnesium exhaustion can cause muscle spasm, hypertension and coronary vasodilator and cerebral vasospasm.As seen many painstaking effort visitor's diseases and neuromuscular function disease all have the exhaustion of magnesium.
4, to gi tract and functions of hormones:
To GI effect, can make oddi's sphincter lax, short-term bile flows out, and impels gall bladder emptying, has choleretic effect.Can reduce intestines wall tension force and wriggling, spasmolysis is arranged.
To functions of hormones, the variation of blood plasma magnesium directly influences the secretion of PTH, and thyroxine can cause that too much serum magnesium reduces, and can improve the requirement of magnesium again, causes relative magnesium deficiency, therefore must the supply magnesium salts to hyperthyroid patient.
Studies show that recently that 5, the free magnesium of endochylema has the critical function of regulating the myocardial cell, as the startup of RNA translation, film potassium ion and calcium channel activity, the release of calcium etc. in the sarcoplasmic reticulum.Magnesium also may activate calcium pump, calcium is pumped in cell, and calcium pump is magnesium dependency Ca
2+The ATP enzyme.
6, magnesium deficiency is to the influence of body:
1), magnesium deficiency and calcium metabolism: the hypocalcemia patient often has significant magnesium deficiency performance, and magnesium exhaustion also can cause serum calcium cancentration significantly to descend.
2), magnesium deficiency and neural muscle excitability: neural muscle excitability is hyperfunction to be the initial performance of magnesium deficiency.That common muscular tremor, brothers jerk is excessive, hyperreflexia, ataxia, hyperacusis and illusion.
3), magnesium deficiency and cardiovascular disorder: the magnesium metabolic disturbance that magnesium deficiency causes is relevant with the generation of various degeneration illness.Cardiovascular disorder is exactly one of them.
Arginine is a kind of basic aminoacids, is important condition amino acid.In some situation such as body development is immature or under stressed condition, if lack arginine, just body can not be kept positive nitrogen balance and normal physiological function.
Arginine is an integral part in the urea cycle, has extremely important physiological function.Eat arginine more, can increase the activity of arginase in the liver, help the ammonia in the blood to be converted into urea and to excrete.Arginic important metabolic function is the healing effect that promotes wound, can promote the synthetic of collagenous tissue.Arginine can prevent the degeneration of thymus gland, and additional arginine can increase the weight of thymus gland, promotes the growth of thymus gland medium size lymphocyte.Arginine can promote the ripe and differentiation of CD cell in bone and the lymphoglandula.In immunity system, except that lymphocyte, cytophagous vigor is also relevant with arginine.After adding arginine, can activate its enzyme system, making it more can the kill tumor cell or target cell such as bacterium.Arginine can stimulate the high glucemia element of Regular Insulin, pancreas in hypophysis secretion tethelin, prolactin and the pancreas, and these hormones have effect to promoting growth, and is relevant with the intravital immunologic function of raising again simultaneously.Arginine is the prerequisite material of synthetic polyamine, and polyamines is that the lymphocyte breeding is essential with growth.Arginine also is the necessary composition in the enzymes metabolism approach of NO and citrulline reaction.It can stimulate these organs and tissue secretion hormone, plays the effect of immunologic function.
Summary of the invention
The invention provides a kind of soft magnesia amino acid-magnesium chelate that is called, the L-L-Argininum Mg of Chelate, its structural formula is:
Molecular formula: C
12H
26N
8MgO
4
Molecular weight: 370.6936 (according to relative atomic weight meters in 1989)
English name: L-Argininum Mg of Chelate
Biological chemistry specific name: little peptide magnesium, amino acid chelated magnesium, L-Argininum Mg of Chelate.
The present invention is set in the micromolecular category of little peptide, and promptly Zui Xiao albumen dipeptides claims little peptide again, and molecular weight is 370.6936, and little peptide is to assemble synthetic under the particular environment with amino acid outside organism, and magnesium elements also assembling simultaneously gets on.According to soft matter theory and Biological Principles, the hard material that will exist in the world originally in organism external application specific method divides the system combination again, be combined into directly adaptable soft material form of life entity, promptly change the not good essence of its original organism assimilation effect, and show the certain effects of design in advance.
The present invention is a carrier with two L-arginine, and two L-arginine have formed the little peptide that is similar to natural dipeptides protein-magnesium with magnesium elements and combined magnesium.The selection reason of carrier is, amino acid is the proteinic minimum unit that forms, and it is the basic substance of life.The gene relevant with heredity in fact also is the amino acid chain of different order.At present, relevant with human body 28 seed amino acids that have.The peptide chain that this 28 seed amino acid is arranged in the different order different lengths is formed the functional protein of body portion.Have 100 multiple proteins according to statistics.Protein in the meals does not directly constitute the protein in the health, but through after digesting and assimilating, mainly is transformed into amino acid in liver, and these amino acid are reassembled into intravital 100 multiple proteins again according to the needs of human body.Therefore, not protein and amino acid is only the nutrient substance that needed by human body is wanted strictly speaking.
The present invention has selected the L-arginine for use, and the L-arginine can increase immunity of organisms, quickens microcirculation, promotes metabolism.Lack arginine and can cause poor growth, immunity degradation.
The present invention does not relate to the quality of biological gene substantially, gene template is when carrying out the life assemblage of aminoacid sequence, this process also is accompanied by the transmittance process and the switching process of energy simultaneously, little peptide small molecules of the present invention provides and quickens the material (power) of this transmittance process and switching process, its basic theory is to talk acquired disposition on the basis of molecular genetics (gene transmission) and molecular epidemiology (genetic flaw) inborn factor, because the environment of the existence of life and its own existence has very important interaction, be what and the quality of quality that nutrient substance provides energy, equally vital process has been played very important influence, the possibility that transgenation may also be arranged of improvement of genes has promptly been arranged.Disease is the spontaneous phenomenon of vital process with failing naturally, and the present invention not only can treat the process that the disease that has occurred can delay the nature deterioration process again, and the generation of prevention some diseases in this process, really accomplishes good health and a long life.
Product of the present invention should be returned and mended magnesium products the 4th class: L-L-Argininum Mg of Chelate, two amino acid of reason form minimum protein and show that it is active essential, so also can be described as little peptide in conjunction with magnesium, with the material class discrimination, are called soft magnesia.Select this seed amino acid to form new molecule, can satisfy the not demand of preventing and treating of same-action, different ages, various disease substantially with combining of magnesium elements.
Product mechanism of action of the present invention: L-arginine magnesium is a kind of stable water-soluble chelate structure, the essence of little peptide binding substances, oral post-absorption is good, can't combine with oxalic acid, the phytic acid in the food and influence absorption, absorpting form with little peptide ammino acid in small intestine is entered in the body by abundant the absorption, does not need to add vitamins D
3Promote to absorb, avoided D
3The danger of poisoning.
Embodiment
The present invention adopts preparation method's preparation of autonomous patent of invention technology (patent No. ZL96116524.3).
Structural formula of the present invention is:
Molecular formula: C
12H
26N
8MgO
4
Molecular weight: 370.6936
Can make tablet, hard capsule, soft capsule, micro-capsule, granule, oral liquid, injection etc. with it during concrete the use; Also can be made into the patch of external application etc.
Product proterties of the present invention: this product is the finely powdered white particle, and odorless is little puckery, soluble in water, is insoluble to organic solvents such as ethanol, ether substantially, has water absorbability.Products characteristics of the present invention: dissolve, good absorption has good benefit magnesium and mends arginic effect, more meets the bioenergy conversion and the physiological requirements of human body.
Indication of the present invention: diseases such as hyperlipidemia, hypertension, diabetes, hyperthyroidism and various types of heart trouble, sacroiliitis, auditory dysesthesia, illusion, osteoporosis, muscular tremor, ataxia, orientation force are not normal can be used for that immunizing power is regulated, promotes growth is grown, antineoplastic auxiliary medical nutritious prod.
Claims (2)
1, a kind of L-L-Argininum Mg of Chelate, the recruit shows following feature:
(1) structural formula is:
(2) molecular formula: C
12H
26N
8MgO
4
(3) molecular weight: 370.6936
2, L-L-Argininum Mg of Chelate according to claim 1; It is characterized in that two L-arginine have formed the little peptide that is similar to natural dipeptides protein-magnesium with magnesium elements and combined magnesium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016924 CN1666977A (en) | 2004-03-12 | 2004-03-12 | L-chelated magnesium arginine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016924 CN1666977A (en) | 2004-03-12 | 2004-03-12 | L-chelated magnesium arginine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1666977A true CN1666977A (en) | 2005-09-14 |
Family
ID=35038286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410016924 Pending CN1666977A (en) | 2004-03-12 | 2004-03-12 | L-chelated magnesium arginine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1666977A (en) |
-
2004
- 2004-03-12 CN CN 200410016924 patent/CN1666977A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schloerb | Immune-enhancing diets: products, components, and their rationales/discussion | |
| Secor et al. | Effects of meal size on postprandial responses in juvenile Burmese pythons (Python molurus) | |
| TWI314452B (en) | Amino acid composition and supplemental solution | |
| CA2702045C (en) | Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine | |
| US5756481A (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction in animals and man | |
| JP2006522821A (en) | Methods and compositions for enhancing anaerobic work capacity in tissues | |
| WO2005107735A2 (en) | Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a | |
| EP0948328B1 (en) | Compositions based on aminoacids | |
| JP2002034592A (en) | Method for producing protein-zinc readily absorbable in body | |
| US20030013763A1 (en) | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | |
| CA2667667C (en) | Solid or aqueous alkaline preparation comprising a creatine component, process for the production thereof and the use thereof | |
| US6812249B2 (en) | Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use | |
| CA2134380C (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
| JPH05344863A (en) | Compositions effective against diabetes | |
| CN1666977A (en) | L-chelated magnesium arginine | |
| Polat et al. | A controlled trial of glutamine effects on bone healing | |
| JP2007161688A (en) | Cartilage formation promoter | |
| CN1041107A (en) | Methods of promoting pig growth | |
| Block et al. | Regulation of rat liver branched-chain α-keto acid dehydrogenase activity by meal frequency and dietary protein | |
| Birkhahn et al. | Potential of the monoglyceride and triglyceride of DL-3-hydroxybutyrate for parenteral nutrition: synthesis and preliminary biological testing in the rat | |
| CN1666980A (en) | L-chelated calcium arginine | |
| JP2008214232A (en) | Collagen synthesis promoter | |
| Peragón et al. | Alterations in the fractional protein turnover rates in rainbow‐trout liver and white muscle caused by an Aminoacid‐based diet and changes in the feeding frequency | |
| CN1666978A (en) | L-chelated calcium lysine | |
| CN1730002A (en) | Effervescence tablet preparation for replenishing nutritious elements to human being and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |